Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on January 14th, the Representative disclosed that they had sold between ...

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed ...

The Tempo pen is currently compatible with three of Lilly's insulin products, including Humalog and Lyumjev, both insulin lispro-based, and insulin glargine brand Basaglar. "Despite technological ...

According to research, one vial of Lilly's Humalog (insulin lispro) cost $21 in 1999, but had increased to $332 in 2019, representing a price increase of 1480%. The PBMs meanwhile stand accused of ...

zinc suspension Humulin L (Lilly) 28 days Prescribing information Insulin lispro (rDNA origin) vial Humalog vial (Lilly) 28 days Prescribing information NPH, human insulin isophane suspension ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Eli Lilly has established itself as a powerhouse in the pharmaceutical industry, with a particular focus on diabetes care, oncology, immunology, and neuroscience. The company's recent success has ...